U.S. Markets open in 1 hr 25 mins

Cleveland Biolabs Countermeasure for Acute Radiation Syndrome, Pipeline Review, and Market Potential

NEW YORK, NY / ACCESSWIRE / August 11, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on Cleveland BioLabs, Inc. (CBLI), a biopharmaceutical company engaged in the development of techniques to activate the immune system to address medical needs. The company's proprietary platform of toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy, and vaccines.

Entolimod Biodefense is the company's most advanced product candidate. It is being developed as a radiation countermeasure to prevent death from Acute Radiation Syndrome (ARS). ARS would be a major cause of fatalities in the event of a nuclear weapon detonation.

Cleveland Biolab's development efforts are related to apoptosis, a regulated form of cell death that can occur in response to exposure to radiation or toxic chemicals. Among other things, apoptosis is largely responsible for the lethality of high-dose radiation exposure.

How close to market is Entolimod Biodefense? This and full pipeline review here: READ MORE.

Copy and paste to your browser may be required to view the report - http://tradersnewssource.com/cleveland-biolabs/.

The market for radiation countermeasures has grown substantially, primarily due to the perceived threat of chemical, biological, radiation, and nuclear attacks. That threat has been exacerbated due to recent tensions with North Korea. In addition to the U.S. government, which maintains a national stockpile of emergency products, potential customers include state and local governments, foreign governments, NGOs, multinational corporations, security companies, healthcare providers, and nuclear power facilities.

Due to the limitations of the two currently approved treatments to deal with a large-scale radiation event, CBLI believes that entolimod is a compelling product candidate.

Read all you need to know about CBLI, a complete pipeline review, and Q1 analysis: READ MORE.

Copy and paste to your browser may be required to view the report - http://tradersnewssource.com/cleveland-biolabs/.


Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles, and reports covering equities listed on NYSE, NASDAQ, and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TNS has not been compensated, directly or indirectly, for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. Ivan Neilson, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise, arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.



SOURCE: Traders News Source